A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2020-03-27
• Target enrollment: 0
• Participant gender: All

Summary

A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Petersburg State Pavlov Medical University
• Treatments: Antibodies, Monoclonal; Bendamustine Hydrochloride; Nivolumab

Criteria

Inclusion Criteria:

• Diagnosis: Histologically confirmed Hodgkin's lymphoma

• Relapsed or refractory to at least two prior treatment lines

• Relapsed after nivolumab treatment or refractory to nivolumab treatment

• Age 18-70 years old

• Signed informed consent

• No severe concurrent illness

Exclusion Criteria:

• Uncontrolled bacterial or fungal infection at the time of enrollment

• Requirement for vasopressor support at the time of enrollment

• Karnofsky index <30%

• Pregnancy

• Somatic or psychiatric disorder making the patient unable to sign informed consent

• Active or prior documented autoimmune disease requiring systemic treatment.